Advanced Patent Sect. 101 Eligibility: Latest Federal Circuit Decisions, PTAB Cases and USPTO 2019 Revised Guidelines

Recording of a 90-minute premium CLE webinar with Q&A


Conducted on Wednesday, June 26, 2019

Recorded event now available

or call 1-800-926-7926
Program Materials

The CLE webinar will provide an advanced discussion of patent eligibility, focusing in great detail on the latest Federal Circuit decisions, Patent Trial and Appeal Board (PTAB) cases, and U.S. Patent and Trademark Office (USPTO) guidance. The panel will offer best practices for navigating the interplay between the Federal Circuit and the USPTO and addressing patent eligibility issues.

Description

The Federal Circuit's recent decision in Cleveland Clinic Foundation et al. v. True Health Diagnostics LLC (Fed. Cir. Apr. 1, 2019) demonstrated that just because a patent satisfies the USPTO's guidelines during prosecution does not mean that the Federal Circuit won’t strike it down. In Cleveland Clinic, the Federal Circuit ignored and, in fact, criticized the USPTO’s guidelines.

In another case [Endo Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (Fed. Cir. Mar. 28, 2019)], the Federal Circuit reversed a decision of invalidity under 35 U.S.C. 101, concluding the method of treatment claims were patent eligible for claiming an application of a natural relationship and not the natural relationship itself.

In Jan. 2019, the USPTO announced revised guidance for subject matter eligibility under section 101. The 2019 Revised Patent Subject Matter Eligibility Guidance revises the procedures for determining whether a patent claim or patent application claim is directed to a judicial exception.

These decisions, among others, serve as a reminder that patent owners must not only consider USPTO guidance when drafting patent applications. They should keep in mind that case law supersedes agency guidance and patent applications would do well to satisfy both federal case law and agency guidance.

Listen as our authoritative panel of patent attorneys examines recent Federal Circuit decisions, the 2019 revised guidelines. The panel will discuss the importance of satisfying both USPTO guidance on section 101 and Federal Circuit section 101 case law. The panel will offer guidance for handling both to get an invention patented.

READ MORE

Outline

  1. Recent Federal Circuit decisions
    1. Cleveland Clinic Foundation v. True Health Diagnostics (Fed. Cir. Apr. 1, 2019)
    2. Natural Alternatives Int’l v. Creative Compounds (Fed. Cir. Mar. 15, 2019)
    3. Endo Pharmaceuticals Inc. v. Teva Pharmaceuticals USA (Fed. Cir. Mar. 28, 2019)
    4. ChargePoint v. SemaConnect (Fed. Cir. Mar. 28, 2019)
    5. Athena Diagnostics Inc. v. Mayo Collaborative Services L.L.C. (Fed. Cir. Feb. 6, 2019)
    6. Other recent decisions
  2. Recent PTAB cases
  3. 2019 revised USPTO guidelines
  4. The interplay between the Federal Circuit and USPTO
  5. Practical guidance for handling both Federal Circuit decisions and USPTO guidance

Benefits

The panel will review these and other priority issues:

  • How do recent decisions from the Federal Circuit impact the drafting of patents?
  • What is the interplay between Federal Circuit decisions and the USPTO revised guidance?
  • What are best practices for patent counsel to demonstrate patent eligibility?

Faculty

Kiklis, Michael
Michael L. Kiklis

Member
Bass Berry & Sims

Mr. Kiklis focuses on PTAB litigation as well as district court patent litigation. He also handles Federal Circuit...  |  Read More

Kunin, Stephen
Stephen G. Kunin

Partner
Maier & Maier

Mr. Kunin represents clients in post-grant patent proceedings at the U.S. Patent and Trademark Office. He also...  |  Read More

Other Formats
— Anytime, Anywhere

Strafford will process CLE credit for one person on each recording. All formats include program handouts. To find out which recorded format will provide the best CLE option, select your state:

CLE On-Demand Video

$347

Download

$347